Selensubstitution bei akutem Myokrdinfarkt

Thiele, R.; Wagner, Daniels; Gassel, M. M.; Winnefeld, K; Pleissner, J.; Pfeifer, Rüdiger

doi:10.1007/bf03041957

Cited by 10 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the daily level in our trial is within the limits considered safe (150 μg maximum; Secretariat of Health Surveillance, Ministry of Health (SVS/MS) Ordinance 40/1998). The inorganic form of Se (sodium selenite) was chosen because it has been shown to prevent Keshan cardiopathy, to reduce electroechocardiographic alterations in patients nourished by the parenteral route and to reduce reinfarction and cardiac death due to acute myocardial infarction [ 50 – 52 ]. Because Chagas heart disease progresses slowly (1% to 3% per year) [ 5 ], this clinical trial will last 5 years.…”

Section: Discussionmentioning

confidence: 99%

Selenium Treatment and Chagasic Cardiopathy (STCC): study protocol for a double-blind randomized controlled trial

Brasil

Souza

Hasslocher‐Moreno

et al. 2014

Trials

View full text Add to dashboard Cite

BackgroundHeart disease progression occurs in 30% of patients with chronic Trypanosoma cruzi infection. Supplementation with selenium (Se) in animal model of T. cruzi infection produced promising results. There is evidence that patients with Chagas heart disease have lower Se levels than healthy individuals and patients with T. cruzi infection without of cardiac disease. The aim of this investigation is to estimate the effect of Se treatment on prevention of heart disease progression in patients with chagasic cardiopathy.MethodsThe Selenium Treatment and Chagasic Cardiopathy trial is a superiority, double-blind, placebo-controlled, randomized clinical trial. The eligibility criteria are as follows: (1) a Chagas disease diagnosis confirmed by serology; (2) segmental, mild or moderate global left ventricular systolic dysfunction; and (3) age between 18 and 65 years. The exclusion criteria are as follows: (1) pregnancy, (2) diabetes mellitus, (3) tobacco use, (4) alcohol abuse, (5) evidence of nonchagasic heart disease, (6) depression, (7) dysphagia with evidence of food residues in the esophagus, (8) dysphagia with weight loss higher than 15% of usual weight in the last four months and/or (9) conditions that may result in low protocol adherence. The intervention will be 100 μg of sodium selenite once daily for 365 consecutive days compared to placebo. The following are the primary outcomes to be measured: (1) the trajectories of the left ventricular ejection fraction in the follow-up period; (2) reduction of heart disease progression rates, with progression defined as a 10% decrease in left ventricular ejection fraction; and (3) rate of hospital admissions attributable to dysrhythmia, heart failure or stroke due to Chagas disease. One hundred thirty patients will be randomly allocated into either the intervention or placebo group at a ratio of 1:1. The sequence allocation concealment and blinding were planned to be conducted with the strategy of numbered boxes. Both patients and health-care providers will remain blinded to the intervention groups during the 5 years of follow-up.DiscussionIf Se treatment reduces the progression of Chagas cardiopathy, the inclusion of this micronutrient in the daily diet can improve the therapeutic regimen for this neglected tropical disease at low cost.Trial registrationClinical Trials.gov ID: NCT00875173 (registered 20 October 20 2008).

show abstract

Section: Discussionmentioning

confidence: 99%

Selenium Treatment and Chagasic Cardiopathy (STCC): study protocol for a double-blind randomized controlled trial

Brasil

Souza

Hasslocher‐Moreno

et al. 2014

Trials

View full text Add to dashboard Cite

show abstract

“…A possible effect of selenium treatment is ascribed to the influence on the sarcolemmal sodium-calcium exchange which in turn contributes to the late phase of the action potential [6]. Finally selenium therapy in the acute phase of myocardial infarction prevented left heart failure to a substantial degree and diminished acute cardiac rhythm disturbances and ventricular extrasystoles [7]. Nowadays our daily intake of selenium mainly depends on fish consumption.…”

Section: Analysis Of An Original Prescription For a Specific Cardiac mentioning

confidence: 98%